CAPTRUST Financial Advisors
SPRY icon

CAPTRUST Financial Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-146
Closed -$1K – 5127
2022
Q1 		$1K Buy
+146
New +$636 ﹤0.01% 4746

Other funds holding SPRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CAPTRUST Financial Advisors's SPRY Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of ARS Pharmaceuticals (SPRY) in Q2 2022, closing a stake of 146 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in SPRY in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 64 funds tracked by Wall St. Rank hold SPRY as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining ARS Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 146 ARS Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in ARS Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's ARS Pharmaceuticals position peaked at $1K in Q1 2022.
  • 64 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.